

- females of different races/ethnicities. *Clin Cosmet Investig Dermatol*. 2015;8:231-238.
25. Villasenor J, Berson DS, Kroshinsky D. Treatment guidelines in adult women. In: Shalita AR, Del Rosso JQ, Webster GF, eds. *Acne Vulgaris*. London, United Kingdom: Informa Healthcare; 2011:198-207.
 26. Berson D, Alexis A. Adapalene 0.3% for the treatment of acne in women. *J Clin Aesthet Dermatol*. 2013;6:32-35.
 27. Del Rosso JQ. Topical therapy for acne in women: is there a role for clindamycin phosphate-benzoyl peroxide gel? *Cutis*. 2014;94:177-182.
 28. Zeichner JA. The efficacy and tolerability of a fixed combination (1.2%) and benzoyl peroxide (3.75%) aqueous gel in adult females with facial acne vulgaris. *J Clin Aesthet Dermatol*. 2015;8:21-25.
 29. Fisk WA, Lev-Tov HA, Sivamani RK. Epidemiology and management of acne in adult women. *Curr Derm Rep*. 2014;3:29-39.
 30. Stein-Gold L. Adapalene 0.1%-benzoyl peroxide 2.5% gel in adult female acne. Poster presented at: Winter Clinical Dermatology Conference; January 16–21, 2015; Maui, Hawaii.
 31. Dréno B, Thiboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. *J Euro Acad Dermatol Venereol*. 2015;29:1096-1106.
 32. Dréno B, Layton AM, Zouboulis CC, et al. Adult female acne: a new paradigm. *J Euro Acad Dermatol Venereol*. 2013;27:1063-1070.
 33. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: a multicenter trial. *J Am Acad Dermatol*. 1996;35:482-485.
 34. Pariser DM, Thiboutot DM, Clark S, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. *Cutis*. 2005;75:145-151.
 35. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. *J Am Acad Dermatol*. 2006;54:242-250.
 36. Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. *J Drugs Dermatol*. 2010;9:549-558.
 37. Hui AM, Shalita AR. Topical retinoids. In: Shalita AR, Del Rosso JQ, Webster GF, eds. *Acne Vulgaris*. London, United Kingdom: Informa Healthcare; 2011:86-94.
 38. Draelos Z, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris. *J Am Acad Dermatol*. 2007;56:439.e1-439.e10.
 39. Tanghetti E, Harper JC, Oefelein MG. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable. *J Drugs Dermatol*. 2012;11:1417-1421.
 40. Pariser DM, Rabinowitz D, Bok-Bolden FE, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris. *J Drugs Dermatol*. 2015;14:1083-1089.
 41. Harper JC. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. *J Drugs Dermatol*. 2015;14:381-384.
 42. Zeichner JA. The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in adult female patients with facial acne vulgaris. *J Clin Aesthet Dermatol*. 2015;8:21-25.
 43. Coley MK, Berson DS, Callendar VD. Overview of treatment principles for skin of color. In: Shalita AR, Del Rosso JQ, Webster GF, eds. *Acne Vulgaris*. London, United Kingdom: Informa Healthcare; 2011:70-85.
 44. Ebeye TL, Berson DS. Acne in pregnancy. In: Shalita AR, Del Rosso JQ, Webster GF, eds. *Acne Vulgaris*. London, United Kingdom: Informa Healthcare; 2011:177-181.